Apparently, it will take more than a next-day driving study to satisfy the FDA's concerns regarding the safety of Transcept Pharmaceuticals Inc.'s insomnia drug Intermezzo, a sublingual formulation of zolpidem that the Point Richmond, Calif.-based firm is hoping to position as the first sleep aid specifically for middle-of-the-night awakening.